Type 2 Diabetes Mellitus Completed Phase 4 Trials for Dapagliflozin (DB06292)

Also known as: Diabetes Mellitus Non-insulin-dependent / Type-2 Diabetes Mellitus / Diabetes Mellitus Type 2 (T2DM) / Diabetes Mellitus Type-2 / Type 2 Diabetes (T2DM) / Diabetes, Type 2 / Diabetes Mellitus, Type 2 (T2DM) / Diabetes Mellitus,Type 2 / Diabetes Type II / Type-II Diabetes Mellitus / Diabetes Mellitus 2 Type / T2DM / Diabetes Mellitus Type II / Type II Diabetes / Diabetes Mellitus, Type 2 / Type 2 Diabetes Mellitus (T2DM) / Diabetes Type Two / Diabetes Mellitus - Type 2 / Diabetes, Type II / Non-Insulin-Dependent Diabetes Mellitus / Diabetes Mellitus. Type 2 / Diabetes Type 2 / Type 2 Diabetes Mellitus (T2D) / Type 2 Diabetes (T2D) / Type II; Diabetes / Type II Diabetes Mellitus / Diabetes Mellitus, Type II / NIDDM / Type-2 Diabetes / Type 2 Diabetes Mellitus(T2DM) / Type 2 Diabetes / Type 2-diabetes / Noninsulin Dependent Diabetes Mellitus, Type II / Diabetes Mellitus Type 2 / Type Two Diabetes Mellitus / T2DM (Type 2 Diabetes Mellitus) / Type-2-diabetes Mellitus / Diabetes mellitus -adult onset / Diabetes mellitus non insulin-dep / Maturity onset diabetes / Diabetes mellitus maturity onset

DBCOND0029752 (Type 2 Diabetes Mellitus)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02327039The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic PatientsTreatment
NCT02956811Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?Treatment
NCT02475070Vildagliptin Versus Dapagliflozin on GlucagonBasic Science
NCT02471404Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With SulphonylureaTreatment
NCT03202563Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)Treatment
NCT02561130Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With ForxigaTreatment
NCT02426541Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes MellitusTreatment
NCT02459353Effect of Dapagliflozin on Glycemic VariabilityTreatment
NCT02157298Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.Treatment
NCT03387683A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes PatientsTreatment
NCT02564926Foxiga Korea Local Phase 4 StudyTreatment
NCT02919345Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial ArteryTreatment
NCT02682563Renoprotective Effects of Dapagliflozin in Type 2 DiabetesPrevention
NCT03178591Effects of DPP4 Inhibitor Versus SGLT2 InhibitorTreatment
NCT03074630Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)Basic Science
NCT03089333Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive SubjectsTreatment
NCT02765204A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 DiabetesTreatment
NCT02429258Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or InsulinTreatment